BLLN logo

BillionToOne, Inc. Stock Price

NasdaqGS:BLLN Community·US$3.7b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author

BLLN Share Price Performance

US$81.84
-27.10 (-24.88%)
US$160.00
Fair Value
US$81.84
-27.10 (-24.88%)
48.9% undervalued intrinsic discount
US$160.00
Fair Value
Price US$81.84
AnalystHighTarget US$160.00

BLLN Community Narratives

AnalystHighTarget·
Fair Value US$160 48.9% undervalued intrinsic discount

Precision Medicine Tailwinds Will Drive Major Upside For This Diagnostics Leader

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$160
48.9% undervalued intrinsic discount
Revenue
47.21% p.a.
Profit Margin
9.93%
Future PE
136.42x
Price in 2028
US$195.77

Trending Discussion

Updated Narratives

BLLN logo

Precision Medicine Tailwinds Will Drive Major Upside For This Diagnostics Leader

Fair Value: US$160 48.9% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

High growth potential with adequate balance sheet.

1 Risk
4 Rewards

BillionToOne, Inc. Key Details

US$254.1m

Revenue

US$88.6m

Cost of Revenue

US$165.6m

Gross Profit

US$176.7m

Other Expenses

-US$11.1m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-0.24
65.15%
-4.36%
30.5%
View Full Analysis

About BLLN

Founded
2016
Employees
620
CEO
Oguzhan Atay
WebsiteView website
www.billiontoone.com

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a test that provides longitudinal determination of cancer burden through methylation assessment. The company was incorporated in 2016 and is headquartered in Menlo Park, California.

Recent BLLN News & Updates

BillionToOne: An Interesting Set-Up Into 2026

Dec 25

Recent updates

No updates